Keybanc analyst Jeffrey Hammond maintains Helios Technologies (NYSE:HLIO) with a Overweight and raises the price target from $71 to $74.
Parkinson’s Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says
Seelos Therapeutics Inc (NASDAQ:SEEL) announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). …